Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 13/20 | 0.50 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946907 | 0.84 | MAPT (0.52) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL6794026 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL2943266 | 0.81 | BCL2L1 (0.59) | BCL2L1MCL1 | |
| SCHEMBL6794022 | 0.78 | MAPT (0.46) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL2951573 | 0.77 | BCL2L1 (0.56) | BCL2L1 | |
| SCHEMBL2481803 | 0.75 | MAPT (0.54) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL1956245 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL2388189 | 0.74 | MAPT (0.55) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL28526212 | 0.73 | MAPT (0.54) | SMN1; SMN2MAPTPKMPOLBGAA | |
| SCHEMBL16037529 | 0.73 | MAPT (0.59) | SMN1; SMN2MAPTPKMPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | SMN1; SMN2 1713/4885MAPT 4806/4885PKM 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.